These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30878493)

  • 1. Systemic PPARγ deletion in mice provokes lipoatrophy, organomegaly, severe type 2 diabetes and metabolic inflexibility.
    Gilardi F; Winkler C; Quignodon L; Diserens JG; Toffoli B; Schiffrin M; Sardella C; Preitner F; Desvergne B
    Metabolism; 2019 Jun; 95():8-20. PubMed ID: 30878493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed Hair Follicle Morphogenesis and Hair Follicle Dystrophy in a Lipoatrophy Mouse Model of Pparg Total Deletion.
    Sardella C; Winkler C; Quignodon L; Hardman JA; Toffoli B; Giordano Attianese GMP; Hundt JE; Michalik L; Vinson CR; Paus R; Desvergne B; Gilardi F
    J Invest Dermatol; 2018 Mar; 138(3):500-510. PubMed ID: 28964716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephropathy in Pparg-null mice highlights PPARγ systemic activities in metabolism and in the immune system.
    Toffoli B; Gilardi F; Winkler C; Soderberg M; Kowalczuk L; Arsenijevic Y; Bamberg K; Bonny O; Desvergne B
    PLoS One; 2017; 12(2):e0171474. PubMed ID: 28182703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pparg-P465L mutation worsens hyperglycemia in Ins2-Akita female mice via adipose-specific insulin resistance and storage dysfunction.
    Pendse AA; Johnson LA; Tsai YS; Maeda N
    Diabetes; 2010 Nov; 59(11):2890-7. PubMed ID: 20724579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatty acid metabolism in patients with PPARgamma mutations.
    Tan GD; Savage DB; Fielding BA; Collins J; Hodson L; Humphreys SM; O'Rahilly S; Chatterjee K; Frayn KN; Karpe F
    J Clin Endocrinol Metab; 2008 Nov; 93(11):4462-70. PubMed ID: 18713822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
    Lüdtke A; Buettner J; Schmidt HH; Worman HJ
    J Med Genet; 2007 Sep; 44(9):e88. PubMed ID: 17766367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction.
    Mallon PW; Sedwell R; Rogers G; Nolan D; Unemori P; Hoy J; Samaras K; Kelleher A; Emery S; Cooper DA; Carr A;
    J Infect Dis; 2008 Dec; 198(12):1794-803. PubMed ID: 18954260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation.
    Guettier JM; Park JY; Cochran EK; Poitou C; Basdevant A; Meier M; Clément K; Magré J; Gorden P
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):547-554. PubMed ID: 18076675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inguinal Fat Compensates Whole Body Metabolic Functionality in Partially Lipodystrophic Mice with Reduced PPARγ Expression.
    Chang CS; Yu SS; Ho LC; Chao SH; Chou TY; Shao AN; Kao LZ; Chang CY; Chen YH; Wu MS; Tsai PJ; Maeda N; Tsai YS
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.
    Lüdtke A; Buettner J; Wu W; Muchir A; Schroeter A; Zinn-Justin S; Spuler S; Schmidt HH; Worman HJ
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2248-55. PubMed ID: 17356052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nervous System Expression of PPARγ and Mutant PPARγ Has Profound Effects on Metabolic Regulation and Brain Development.
    Stump M; Guo DF; Lu KT; Mukohda M; Cassell MD; Norris AW; Rahmouni K; Sigmund CD
    Endocrinology; 2016 Nov; 157(11):4266-4275. PubMed ID: 27575030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adipose-specific knockout of SEIPIN/BSCL2 results in progressive lipodystrophy.
    Liu L; Jiang Q; Wang X; Zhang Y; Lin RC; Lam SM; Shui G; Zhou L; Li P; Wang Y; Cui X; Gao M; Zhang L; Lv Y; Xu G; Liu G; Zhao D; Yang H
    Diabetes; 2014 Jul; 63(7):2320-31. PubMed ID: 24622797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPARγ and Diabetes: Beyond the Genome and Towards Personalized Medicine.
    Cataldi S; Costa V; Ciccodicola A; Aprile M
    Curr Diab Rep; 2021 Apr; 21(6):18. PubMed ID: 33866450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPAR gamma gene--a review.
    Janani C; Ranjitha Kumari BD
    Diabetes Metab Syndr; 2015; 9(1):46-50. PubMed ID: 25450819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for interaction between PPARG Pro12Ala and PPARGC1A Gly482Ser polymorphisms in determining type 2 diabetes intermediate phenotypes in overweight subjects.
    Ruchat SM; Weisnagel SJ; Vohl MC; Rankinen T; Bouchard C; Pérusse L
    Exp Clin Endocrinol Diabetes; 2009 Oct; 117(9):455-9. PubMed ID: 19536736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse adipose phenotype and hyperinsulinemia in gravid mice deficient in placental growth factor.
    Hemmeryckx B; van Bree R; Van Hoef B; Vercruysse L; Lijnen HR; Verhaeghe J
    Endocrinology; 2008 May; 149(5):2176-83. PubMed ID: 18258676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of PPARG and LPIN1 gene polymorphisms with metabolic syndrome and type 2 diabetes.
    Bego T; Dujic T; Mlinar B; Semiz S; Malenica M; Prnjavorac B; Ostanek B; Marc J; Causević A
    Med Glas (Zenica); 2011 Feb; 8(1):76-83. PubMed ID: 21263402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fat Mass Reduction With Adipocyte Hypertrophy and Insulin Resistance in Heterozygous PPARγ Mutant Rats.
    Gumbilai V; Ebihara K; Aizawa-Abe M; Ebihara C; Zhao M; Yamamoto Y; Mashimo T; Hosoda K; Serikawa T; Nakao K
    Diabetes; 2016 Oct; 65(10):2954-65. PubMed ID: 27381370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A complicated pregnancy in a patient with lipodystrophic diabetes attributable to a peroxisome proliferator-activated receptor gamma (PPARG) mutation.
    Madhra M; Noh RM; Zammitt NN; Patrick AW; Love CD
    Diabet Med; 2012 Oct; 29(10):e398-401. PubMed ID: 22803842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.
    Auclair M; Vigouroux C; Boccara F; Capel E; Vigeral C; Guerci B; Lascols O; Capeau J; Caron-Debarle M
    Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):829-38. PubMed ID: 23393388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.